These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36186882)

  • 41. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Zarate CA
    Bipolar Disord; 2015 Jun; 17(4):438-43. PubMed ID: 25400146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
    Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
    Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.
    An D; Wei C; Wang J; Wu A
    Front Psychol; 2021; 12():648691. PubMed ID: 34140915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
    Tham JCW; Do A; Fridfinnson J; Rafizadeh R; Siu JTP; Budd GP; Lam RW
    Int Clin Psychopharmacol; 2022 Sep; 37(5):206-214. PubMed ID: 35695279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
    Zhou YL; Wu FC; Wang CY; Zheng W; Lan XF; Deng XR; Ning YP
    J Affect Disord; 2020 Nov; 276():608-615. PubMed ID: 32871692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
    Diazgranados N; Ibrahim L; Brutsche NE; Newberg A; Kronstein P; Khalife S; Kammerer WA; Quezado Z; Luckenbaugh DA; Salvadore G; Machado-Vieira R; Manji HK; Zarate CA
    Arch Gen Psychiatry; 2010 Aug; 67(8):793-802. PubMed ID: 20679587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
    Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
    Zarate CA; Brutsche NE; Ibrahim L; Franco-Chaves J; Diazgranados N; Cravchik A; Selter J; Marquardt CA; Liberty V; Luckenbaugh DA
    Biol Psychiatry; 2012 Jun; 71(11):939-46. PubMed ID: 22297150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
    Moaddel R; Luckenbaugh DA; Xie Y; Villaseñor A; Brutsche NE; Machado-Vieira R; Ramamoorthy A; Lorenzo MP; Garcia A; Bernier M; Torjman MC; Barbas C; Zarate CA; Wainer IW
    Psychopharmacology (Berl); 2015 Jan; 232(2):399-409. PubMed ID: 25056852
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
    Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
    Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
    Wilkinson ST; Ballard ED; Bloch MH; Mathew SJ; Murrough JW; Feder A; Sos P; Wang G; Zarate CA; Sanacora G
    Am J Psychiatry; 2018 Feb; 175(2):150-158. PubMed ID: 28969441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
    Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
    Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation.
    Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; McIntyre RS; Ning Y
    J Affect Disord; 2022 May; 304():78-84. PubMed ID: 35176337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
    Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; Wu K; McIntyre RS; Ning Y
    J Psychiatr Res; 2021 Dec; 144():312-319. PubMed ID: 34715598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
    Feeney A; Hock RS; Freeman MP; Flynn M; Hoeppner B; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Fava M; Papakostas GI
    Eur Neuropsychopharmacol; 2021 Aug; 49():122-132. PubMed ID: 34090255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.